Kornimate/medical-research-clean huggingface dataset:
a new ebv related technologies of t cells in treating malignant tumors and clinical application

Conditions: Nasopharyngeal Neoplasms

Summary: the purpose of this study is to evaluate the safety of the designed lmp1-car -t cells and determine whether the car-t cells are effective in the treatment of ebv associated malignant tumors.

half of the patients will treat with lmp1-car-t cells,while the other half will receive a placebo.during the time of the treatment ,we will supervise the side effect of treated group.at last we compare the survival rate and health condition of the two groups.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of nasopharyngeal carcinoma exclusion criteria: * •pregnant woman * severe autoimmune diseases * serious infection

Keywords: nasopharyngeal carcinoma ebv related cancers
metagenomic analysis of gut microbiome in korean patients with ulcerative colitis

Conditions: Ulcerative Colitis

Summary: the researchers will investigate gut microbiome in korean patients with ulcerative colitis and normal control subjects using metagenomic analysis to elucidate the significant difference between two groups this study will help to understand the association between gut microbiome and inflammatory bowel disease.


Eligibility criteria:
inclusion criteria: * between the age of 19 and 75 years * willing to consent/undergo necessary procedures * clinically active or inactive ulcerative colitis exclusion criteria: * inability to provide informed consent or * clinically severe or fulminant ulcerative colitis * previous abdominal surgery * pregnancy * clinically or laboratory-confirmed gastroenteritis for at least 3 months before sampling * the use of antibiotics in the past a month before sampling * the use of probiotics in the past a month before sampling * severe cardiovascular or pulmonary disease * severe convulsive disorder and current use of anti-convulsive medication * malignancy * transplantation

Keywords: ulcerative colitis gut microbiome metagenomics
plasmapheresis: a multi-modal approach

Conditions: Plasmapheresis; Haematology; Sport Performance; Body Composition; Inflammation; Immunology; Adverse Events

Summary: only very few studies have prospectively looked at the effect of repeated intensive plasma donation. in collaboration with the rode kruis vlaanderen, we have recently found that repeated whole blood donation with a 3-month interval in between induced a drop in markers for iron status, which worsened with the number of donations. the repetition effect of the donations, whether whole blood or plasma, can be different from the effects measured after one single donation. it is therefore critical to test and document this repetitive effect to build trustable and valid guidelines concerning repetitive plasma donation.


Eligibility criteria:
inclusion criteria: * male, * age between 18-50 years * bmi between 20-28 kg/m2 * aptitude to perform maximal physical efforts assessed by the physical activity readiness questionnaire (par-q) exclusion criteria: * the specific exclusion criteria of the rode kruis vlaanderen for blood donation will not be systematically applied to the present study to increase the pool of recruitment. * in case the subjects do not comply with the criteria of the rode kruis vlaanderen, their plasma donations will be thrown away. * in case the subjects comply, their plasma donations will be handled as usually. * the criteria will be assessed before each plasma donation by a questionnaire as usually done in the center of the rode kruis.
coroflex isar neo "all comers" post market clinical follow-up (pmcf)

Conditions: Coronary Artery Disease

Summary: the aim of the study is to assess the safety and efficacy of the device to treat coronary de novo and restenotic lesions.

post-authorisation / after conformité européene (ce) marking coroflex® isar neo is a drug eluting stent system which is an improved version of the predecessor device coroflex® isar which was extensively studied in the isar 2000 registry. the rationale of this observational, post-market, single-armed study is to confirm the safety and efficacy of coroflex® isar neo, also as part of the manufacturer's post-market surveillance obligations in particular for the re-certification of the device.

Eligibility criteria:
inclusion criteria: coroflex® isar neo is intended to be used for * all common significant coronary lesions * target lesion length \>34mm need to be covered with at least 2 stents * patients eligible for this study must be at least 18 years of age. * the patient must fulfill the standard recommendations for percutaneous coronary intervention (pci) based on the last european society of cardiology (esc) recommendations within his/ her regular treatment or that the use of the product has already been decided within the regular planning of the patient's treatment. exclusion criteria: * intolerance to sirolimus and/or probucol * allergy to components of the coating * pregnancy and lactation * complete occlusion of the treatment vessel because of an unsuccessfully re-canalized * cardiogenic shock * risk of an intraluminal thrombus * hemorrhagic diathesis or another disorder such as gastro-intestinal ulceration or cerebral circulatory disorders which restrict the use of platelet aggregation inhibitor therapy and anti-coagulation therapy * surgery shortly after myocardial infarction with indications of thrombus or poor coronary flow behavior * severe allergy to contrast media * lesions which are untreatable with pci or other interventional techniques * patients with an ejection fraction of \< 30 % * vascular reference diameter \< 2.00 mm * treatment of the left stem (first section of the left coronary artery) * indication for a bypass surgery * contraindication for whichever accompanying medication is necessary
the role of snp of ecm and mmp on the development of pathological high myopia

Conditions: Myopia

Summary: to study the clinical characteristics and inheritance of pathological myopia in taiwanese patients.

high myopia (pathological myopia) is caused by excessive axial elongation that primarily involves the ora-equatorial area and the posterior pole. pathological myopia often accompanied by glaucoma, cataracts, macular degeneration, and retinal detachment, leading to blindness when the damage to the retina is extremely severe. population and family studies in chinese have provided evidence for a geneticcomponent to pathologic myopia. children of myopic parents are more likely to have myopia than are children of nonmyopic parents. therefore, it is possible to search a potential candidate gene for myopia through the genomic study of pathological myopia. the retina receives the signal from the retina-rpe complexes and affects the growth of scleral coats. the changes of scleral components, collagen fibrils and proteoglycans, are noted in experimental and human myopia and induce the pathology of high myopia. it is interesting to know that individual difference of snp in the components of scleral coat affects the response to the signal from retina-rpe complexes. the most important effectors in scleral coats are collagens, proteoglycans, mmps and timps. therefore, the difference of snps in different genes might contribute the formation of scleral thinning during myopia development. in this project, we will focus on this subject by using genomelab snpstream genotyping system which is powerful and helpful for identify some specific snps in the regard.

Eligibility criteria:
inclusion criteria: * they are unrelated chinese subjects with high myopia ≦-6.00d. the diagnosis of myopia is determined by the refractive error. anisometropic individuals, with a refractive error of ≦-6.00 d for one eye and ≦-6.00 d for the other eye, with at least a 2-d difference between the two eyes, are considered unaffected exclusion criteria: * individuals are excluded if there is known ocular disease or insult that could predispose to myopia, such as retinopathy of prematurity or early-age media opacification, or if they had a known genetic disease associated with myopia, such as stickler or marfan syndrome.

Keywords: high myopia, genomic
markers of airway inflammation in bal fluid from children with asthma

Conditions: Asthma

Summary: the study compares the biochemical markers in bronchoalveolar lavage samples from asthmatic children to those markers found in non-asthmatic children with other respiratory diseases. the investigators hypothesize that certain markers will be associated specifically with asthma.


Eligibility criteria:
inclusion criteria: * 18 years of age or younger * scheduled for bronchoscopy at national jewish health for persistent asthma, persistent, poorly controlled wheezing, chronic cough, gerd, atelectasis, bronchopulmonary dysplasia, infection. * consent and assent from parent and patient \[if appropriate\]. exclusion criteria: * unwillingness to consent/assent to retrieval of bal fluid for research analysis.

Keywords: asthma inflammation bronchoscopy
a study evaluating ds-1055a in participants with relapsed or refractory locally advanced or metastatic solid tumors

Conditions: Solid Tumor; Advanced Cancer; Metastatic Solid Tumor

Summary: the purpose of this study is to assess the safety and tolerability of ds-1055a in participants with relapsed or refractory locally advanced or metastatic solid tumors for which no standard treatment is available.

this phase 1, open-label, non-randomized, dose escalation, first-in-human study will assess the safety and tolerability of ds-1055a, determine the maximum tolerated dose of ds-1055a, pharmacokinetic (pk) properties of ds-1055a, and the incidence of anti-drug antibodies (adas) against ds-1055a and other antibodies.

Eligibility criteria:
inclusion criteria: * has a histopathologically documented locally advanced or metastatic head and neck, gastric, esophageal cancer, non-small cell lung cancer, or melanoma. participants with other types of solid tumors may be eligible following discussion with the sponsor. * has a relapsed or refractory disease that is not amenable to curative standard therapy. * is 18 years of age or older. * has an eastern cooperative oncology group performance status (ecog ps) of 0-1, with no deterioration for two weeks. * has a measurable disease based on response evaluation criteria in solid tumors (recist) version 1.1. * has adequate organ function within 7 days before enrollment. * is able to provide written informed consent and is willing and able to comply with the protocol. exclusion criteria: * has a concurrently active second malignancy, other than adequately treated non-melanoma skin cancers, in situ melanoma or in situ cervical cancer. participants with history of the second malignancy have been disease-free for \<3 years. * has a history of (non-infectious) interstitial lung disease (ild) that required steroids, currently has ild, or when suspected ild cannot be ruled out by imaging at screening. * has a history of severe pulmonary compromise or requirement of supplemental oxygen within 6 months before enrollment. * has active hepatitis b or hepatitis c virus infection. * has received prior immunotherapy with a grade 3 or higher, or any unresolved ≥grade 2 immune-related adverse event.

Keywords: solid tumor advanced cancer metastatic solid tumor ds-1055a
efficacy of pigmented rice on reducing cardiometabolic risk factors among filipino adults

Conditions: Dyslipidemias; Overweight or Obesity; Hyperglycaemia (Non Diabetic)

Summary: the primary purpose of this clinical trial is to investigate whether the consumption of pigmented rice (black rice) in the diet improves cardiovascular health, specifically body weight, lipids, and glucose levels. it also aims to know whether people enjoyed eating pigmented rice and if they would continue eating it.

the goal of this clinical trial is to test if pigmented rice consumption can lower the cardiometabolic risk factors of adults. the main question\[s\] it aims to answer are: * will pigmented rice significantly reduce lipid levels compared to white rice after six weeks? * will pigmented rice significantly reduce glucose levels compared to white rice after six weeks? will pigmented rice significantly reduce weight and waist-hip ratio levels compared to white rice after six weeks? what are the participants' experiences in consuming pigmented rice? participants will consume black-pigmented rice for six weeks while maintaining their usual physical activity. researchers will compare the white rice group and the black rice group to see if lowers cardiometabolic risk factors.

Eligibility criteria:
inclusion criteria: * aged 20-59 years. * body mass index between 18.5 -35 kg/m2 * elevated cholesterol (total cholesterol \>200 mg/dl or ldl cholesterol 130-190 mg/dl), and/or impaired fasting glucose (100-125mg/dl) * eat rice as a staple food at least twice per day exclusion criteria: * are pregnant or lactating * regularly consume pigmented rice (two meals per day in the past 4 weeks) * have cardiovascular disease (hypertension, stroke, ischemic heart disease, myocardial infarction, or congestive heart failure) or diabetes mellitus * take cholesterol or glucose-lowering medications * have elevated blood pressure (\>130/80 mmhg) * have an illness that may influence lipid metabolism or metabolic rate (liver cirrhosis, pancreatitis, chronic kidney disease, hyperthyroidism, hypothyroidism) * take supplements that may influence lipids and glucose levels (including polyphenols) * are on a strict diet regimen (calorie-restricted or excluding food groups, examples: (examples: ketogenic diet, intermittent fasting, no rice diet) * have an active lifestyle (ex. goes to the gym daily, regularly (≥3 times a week) and perform vigorous activities such as lifting weights, swimming, cycling fast or uphill, or running, or athlete)

Keywords: pigmented rice dyslipidemia hyperglycemia
pd-1 inhibitor combined with azacytidine and homoharringtonine，cytarabine, g-csf for refractory or relapsed aml

Conditions: Immunotherapy; Refractory Leukemia; Relapsed Adult AML; Acute Myeloid Leukemia

Summary: this is an single center, single arm, phase 3 study to evaluate efficacy and safety of pd-1 inhibitor combined with dna methyltransferase inhibitor azacytidine and hag regimen for patients with relapsed and refractory acute myeloid leukemia.

treatment for acute myeloid leukemia（aml） that has not responded to treatment (refractory) or has returned after treatment (relapsed) often do not work. researchers want to see if an immunotherapy drug, combined with a less intense chemotherapy, may be able to help.

Eligibility criteria:
inclusion criteria: * chinese guidelines for the diagnosis and treatment of relapsed and refractory acute myeloid leukemia (2017 edition)，excludes acute promyelocytic leukemia (m3、apl) * hematopoietic stem cell transplantation ≥3 months, discontinue immunosuppressant ≥3 weeks, patients without graft-versus-host disease； * be at least 18 years of age on day of signing informed consent. * have a performance status of less than or equal to 2 on the eastern cooperative oncology group（ecog） performance scale * demonstrate adequate organ function as defined below, all screening labs should be performed before treatment initiation： 1. alt(sgpt) less than or equal to 2.5 × upper limit of norma（uln）； 2. ast (sgot) less than or equal to 2.5 × uln； 3. serum total bilirubin less than or equal to 2.0 × uln note: if total bilirubin \>2.0×uln, subjects with gilbert syndrome records are allowed to join the group 4. serum creatinine ≥ 30 ml/min 5. total white blood cell (wbc) count ≤10,000/µl； note: hydroxyurea therapy is allowed to reduce white blood cells to meet this inclusion criteria.white blood cells should be determined ≥24 hours after the last hydroxyurea administration. final hydroxyurea administration should not ≤3 days prior to the first azacytidine administration. * treatment without anthracycline or demethylation. ability to comprehend the investigational nature of the study and provide informed consent exclusion criteria: * patients with chronic myeloid leukemia，aml of other myeloproliferative disorders malignant neoplasms with other progression those who can not control severe infections and other underlying diseases can not tolerate chemotherapy patients with cardiac insufficiency： ejection fraction (ef)\<30%，new york heart association（nyha） standards，cardiac insufficiency ii or above patients with liver and kidney dysfunction：serum bilirubin (sb)≥2mg/dl，ast is 2.5 times higher than normal upper limit, serum creatinine (scr) is more than 2.5 mg/dl serious mental illness uncooperative refusal to join the study

Keywords: acute myeloid leukemia refractory or relapsed azacytidine hag regimen pd-1 inhibitor
clopidogrel optimal loading dose usage to reduce recurrent events/optimal antiplatelet strategy for interventions

Conditions: Acute Coronary Disease; Angina Unstable

Summary: the purpose of this study is to evaluate whether a higher dosage of clopidogrel with aspirin (two doses) will decrease the risk of ischemic complications (cardiac death (cv death), myocardial infarction (mi), stroke) after a percutaneous coronary intervention (pci).


Eligibility criteria:
inclusion criteria: * diagnosed with acute coronary disease with clinical symptoms and at least electrocardiogram changes or cardiac enzymes elevated exclusion criteria: * use of anticoagulants within 10 days with an international normalized ratio (inr) \> 1.5 or planned use during the hospitalisation period * administration of clopidogrel \> 75 mg prior to randomization * contraindication to clopidogrel or aspirin * active bleeding or significant risk of bleeding

Keywords: platelet aggregation inhibitors acute coronary disease percutaneous coronary
phase i-ii trial of dendritic cell vaccine to prevent covid-19 in adults

Conditions: COVID-19

Summary: this is an adaptive phase i-ii trial of a vaccine consisting of autologous dendritic cells previously loaded ex vivo with sars-cov-2 spike protein, with or without gm-csf, to prevent covid-19 in adults.

subjects eligible for treatment will be those who at baseline, are not actively infected with sars-cov-2, have no evidence of prior infection with sars-cov-2 based on serologic testing, and give informed consent for a vaccination with av-covid-19. the patient population will include the elderly and others at higher risk for poor outcomes after covid-19 infection. for this reason, individuals will not be excluded solely on the basis of age, body mass index, history of hypertension, diabetes, cancer, or autoimmune disease. after enrolling for screening, subjects will undergo a nasal swab test to exclude active covid-19 infection and a rapid test for anti-coronavirus antibodies to exclude pre-existing anti-sars-cov-2 antibodies. 50 ml of blood will be collected, from which peripheral blood monocytes will be isolated and differentiated into dc before incubation with sars-cov-2 s-protein, during which time the protein is digested into 9 to 25 amino acid peptide sequences presented on the dendrites of dc in conjunction with histocompatibility class i and class ii molecules. safety and quality testing will be performed on a small quantity of the batch, and the remaining av-covid-19 will be cryopreserved for shipping to the treatment site. once the study drug is ready, if eligible, the subject will be seen at study week-0 for treatment. prior to injection of the study drug, a nasal swab test will be collected to confirm that they are still negative for covid-19, and blood will be drawn to determine baseline levels of anti-sars-cov-2 antibodies. at the treatment site, the product will be thawed and admixed with saline or (saline with gm-csf), and within 5 hours of thawing, will be injected sc via a 25-gauge needle

Eligibility criteria:
inclusion criteria: * 18 years or older, in relatively good health with adequate physical and mental function, including factors associated with in increased risk for medical complications associated with covid-19 infection or increased risk for exposure to sars-cov-2 exclusion criteria: * active covid-19 infection by pcr testing, pre-existing igg or igm sars-cov-2 antibodies, pregnant, known hypersensitivity to gm-csf, known active immune deficiency disease or active hiv, hbv, hcv, on active treatment with corticosteroids or other immunosupressive agent, participated in previous covid-19 vaccine study
hemorrhagic brainstem cavernous malformations treatment with sirolimus: asingle centre, randomized, placebo-controlled pilot trial

Conditions: Cavernous Malformations; Intracerebral Hemorrhage; Brainstem Stroke

Summary: the aim of this pilot phase trial is to assess the safety and tolerability, and estimate the efficacy of sirolimus in reducing the incidence of ich during high-risk periods for rebleeding, compared to placebo. this pilot trial will inform the design of a future definitive clinical trial on sirolimus treatment for ccm.


Eligibility criteria:
inclusion criteria: 1. age 18-65 years, any gender; 2. patients who have experienced their first symptomatic bscm ich within the six months before randomisation; 3. diagnosed with solitary bscm through t2, gre/t2\*, or swi mr imaging; 4. ich within or around the bscm confirmed by ct /mr; 5. capable of signing an informed consent form with the accompaniment and understanding of a guardian. exclusion criteria: 1. cancer history; 2. pregnancy or lactation; 3. sirolimus/starch allergy; 4. modified rankin scale (mrs) score 5, respiratory failure or currently severe bleeding requiring life support treatment; 5. abnormal liver and/or kidney function (transaminase levels greater than 50, creatinine greater than 110), abnormal white blood cell/platelet counts (white blood cell count below 3.5 or above 9.5 x 109/l or exceeding normal values, platelet count below 100 or above 300); 6. history of previous immunosuppressive therapy; 7. history of prior surgical intervention for ccm ; 8. history of prior cranial radiation therapy ; 9. familial ccm or people with multiple ccm; 10. patients with concurrent acute active infections (e.g., severe bacterial, viral, or fungal infections); 11. uncontrolled diabetes mellitus; 12. currently participating in another clinical trial; 13. patient unwilling/unable to undergo mri. 14. co-administration of drugs affecting cyp3a4 enzymes (ketoconazole, voriconazole, itraconazole, telithromycin, clarithromycin).

Keywords: cavernous malformations brainstem rebleeding rate sirolimus